Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pulmatrix, Inc.    PULM

PULMATRIX, INC.

(PULM)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2020 05/19/2020 05/20/2020 05/21/2020 05/22/2020 Date
1.6(c) 1.72(c) 1.88(c) 1.92(c) 1.88(c) Last
768 591 1 087 329 1 641 526 1 526 277 590 326 Volume
+5.26% +7.50% +9.30% +2.13% -2.08% Change
More quotes
Financials (USD)
Sales 2020 2,76 M - -
Net income 2020 -28,4 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,39x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -31,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,31x
Yield 2021 -
Capitalization 47,8 M 47,8 M -
Capi. / Sales 2020 17,3x
Capi. / Sales 2021 -
Nbr of Employees 23
Free-Float 100,0%
More Financials
Company
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for... 
More about the company
Latest news on PULMATRIX, INC.
05/14PULMATRIX : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/14PULMATRIX, INC. : Results of Operations and Financial Condition, Financial State..
AQ
05/14PULMATRIX : Reports Q1 2020 Results
PR
05/14PULMATRIX : 4/a
PU
05/14PULMATRIX : Defa14a
PU
05/14PULMATRIX : Def 14a
PU
04/24PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
04/22PULMATRIX, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/20PULMATRIX, INC. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
04/16PULMATRIX, INC. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
04/16PULMATRIX : Announces $8.0 Million Registered Direct Offering Priced At-the-Mark..
PR
04/16PULMATRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/16PULMATRIX : and Sensory Cloud Announce Partnership to Develop and Commercialize ..
PR
04/15PULMATRIX, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
04/06PULMATRIX, INC. : Shareholder Director Nominations (form 8-K)
AQ
More news
News in other languages on PULMATRIX, INC.

- No features available -

More news
Chart PULMATRIX, INC.
Duration : Period :
Pulmatrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULMATRIX, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 10,00 $
Last Close Price 1,88 $
Spread / Highest target 432%
Spread / Average Target 432%
Spread / Lowest Target 432%
EPS Revisions
Managers
NameTitle
Teofilo Raad President, Chief Executive Officer & Director
Michael John Higgins Chairman
Michelle Siegert Secretary, Treasurer & Vice President-Finance
Rusty Clayton Medical Director
Steven H. Gillis Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX, INC.118.60%48
GILEAD SCIENCES12.87%91 996
VERTEX PHARMACEUTICALS30.15%73 883
REGENERON PHARMACEUTICALS51.78%63 465
WUXI APPTEC CO., LTD.16.15%23 998
GENMAB A/S36.82%19 339